CA3255376A1 - CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS - Google Patents

CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS

Info

Publication number
CA3255376A1
CA3255376A1 CA3255376A CA3255376A CA3255376A1 CA 3255376 A1 CA3255376 A1 CA 3255376A1 CA 3255376 A CA3255376 A CA 3255376A CA 3255376 A CA3255376 A CA 3255376A CA 3255376 A1 CA3255376 A1 CA 3255376A1
Authority
CA
Canada
Prior art keywords
prmt5 inhibitor
compound
cancer
administering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3255376A
Other languages
English (en)
French (fr)
Inventor
Brian Belmontes
Edward Lau Yue Chan
Paul Hughes
Katherine Slemmons
Jan Sun
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3255376A1 publication Critical patent/CA3255376A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3255376A 2022-04-08 2023-04-07 CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS Pending CA3255376A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329010P 2022-04-08 2022-04-08
US63/329,010 2022-04-08
US202263345736P 2022-05-25 2022-05-25
US63/345,736 2022-05-25
PCT/US2023/017805 WO2023196545A1 (en) 2022-04-08 2023-04-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Publications (1)

Publication Number Publication Date
CA3255376A1 true CA3255376A1 (en) 2023-10-12

Family

ID=86328467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3255376A Pending CA3255376A1 (en) 2022-04-08 2023-04-07 CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS

Country Status (14)

Country Link
US (1) US20250228861A1 (https=)
EP (1) EP4504199A1 (https=)
JP (1) JP2025511399A (https=)
KR (1) KR20240169712A (https=)
CN (1) CN119317435A (https=)
AU (1) AU2023249277A1 (https=)
CA (1) CA3255376A1 (https=)
CL (1) CL2024003040A1 (https=)
IL (1) IL315996A (https=)
JO (1) JOP20240223A1 (https=)
MX (1) MX2024012431A (https=)
TW (1) TW202345844A (https=)
WO (1) WO2023196545A1 (https=)
ZA (1) ZA202407596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
EP4637774A1 (en) * 2022-12-21 2025-10-29 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
AU2024356380A1 (en) * 2023-10-06 2026-04-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
TW202519223A (zh) * 2023-10-31 2025-05-16 大陸商康百達（四川）生物醫藥科技有限公司 一種吡啶衍生物及其在醫藥上的應用
WO2025098450A1 (zh) * 2023-11-08 2025-05-15 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
WO2025113703A1 (zh) * 2023-12-01 2025-06-05 上海翰森生物医药科技有限公司 四并环类衍生物抑制剂、其制备方法和应用
WO2025157284A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和化疗剂的药物组合物
WO2025157287A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和egfr抑制剂的药物组合物
WO2025176054A1 (zh) * 2024-02-20 2025-08-28 华润医药研究院（深圳）有限公司 三环杂环类化合物及其制备方法和医药用途
WO2025194059A1 (en) * 2024-03-15 2025-09-18 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
WO2025207705A1 (en) * 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025213154A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025265110A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129832A1 (en) * 2019-02-13 2020-08-20 Les Laboratoires Servier Combination therapies for use in treating cancer
JP7787819B2 (ja) * 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors

Also Published As

Publication number Publication date
EP4504199A1 (en) 2025-02-12
AU2023249277A1 (en) 2024-10-17
TW202345844A (zh) 2023-12-01
CL2024003040A1 (es) 2025-02-21
WO2023196545A1 (en) 2023-10-12
ZA202407596B (en) 2025-06-25
US20250228861A1 (en) 2025-07-17
KR20240169712A (ko) 2024-12-03
MX2024012431A (es) 2024-11-08
JOP20240223A1 (ar) 2024-10-06
CN119317435A (zh) 2025-01-14
IL315996A (en) 2024-11-01
JP2025511399A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
US20250228861A1 (en) Cancer Treatments Using MTA-Cooperative PRMT5 Inhibitors
AU2007299080B2 (en) Method for treating cancer harboring EGFR mutations
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2762573C2 (ru) Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
RU2429838C2 (ru) Комбинированная химиотерапия
JP2002525320A (ja) アセチルジナリンとジェムシタビン、キャペシタビンまたはシスプラチンの組み合わせによる癌の化学療法
JP2012515184A (ja) 大腸がんの治療方法
CA2902144C (en) Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
WO2024137778A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
JP2011524423A (ja) Ｈｋｉ−２７２とビノレルビンとを含有する抗悪性腫瘍剤の組合せ
CN101516376A (zh) 用于治疗携带egfr突变的癌症的方法
Vansteenkiste et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
US11890292B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
JP2024531492A (ja) Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
CN117083086A (zh) 腺苷二磷酸核糖在放射和／或抗癌治疗辅助疗法中的应用
AU2023400635A1 (en) Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor
JP2023509191A (ja) 癌を治療するための組み合わせ療法
EA052060B1 (ru) Виды лечения рака с применением ингибиторов prmt5, действующих совместно с mta
HK40121791A (zh) 利用mta协作的prmt5抑制剂的癌症治疗
JP2013513614A (ja) 膵臓癌を処置する方法
EP4591866A1 (en) Use of hypoxia-activated compound in preparation of medicament for treating cancer patient
TW202602455A (zh) 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
TW202606706A (zh) 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的胃腸癌治療
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241002

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250106

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250106

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250327

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250327

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250707

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250709

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250924

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319